HsCRP in patients with acute exacerbation of chronic obstructive pulmonary disease

Iranian Red Crescent Medical Journal

Volumn 13, Issue 10, 2011, Pages 713-718

  Alavi, S A ^a   Soati, F ^a   Forghanparast, K ^a   Amani, H ^a  

^a GUILAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

C reactive protein; Chronic obstructive pulmonary disease; Diagnosis

Indexed keywords

C REACTIVE PROTEIN; HEMOGLOBIN;

ADULT; AGED; ARTERIAL CARBON DIOXIDE TENSION; ARTERIAL OXYGEN TENSION; ARTICLE; BODY MASS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COST EFFECTIVENESS ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HEMOGLOBIN BLOOD LEVEL; HOSPITAL ADMISSION; HUMAN; MAJOR CLINICAL STUDY; MALE; SMOKING; SPIROMETRY;

EID: 80755129113     PISSN: 20741804     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. GOLD - The Global Initiative for Chronic Obstructive Lung Disease. Available in www.goldcopd.com.
2. Qaseem A, Snow V, Shekelle P, Sherif K, Wilt TJ, Weinberger S, Owens DK; Clinical Efficacy Assessment Subcommittee of the American College of Physicians. Diagnosis and management of stable chronic obstructive pulmonary disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2007;147: 633-8. [17975186]
3. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. National Guideline Clearinghouse. 2008.
4. Maclay JD, Rabinovich RA, MacNee W. Update in chronic obstructive pulmonary disease 2008. Am J Respir Crit Care Med 2009;179:533-41. [19318543] [http://dx.doi.org/10.1164/rccm.2009 01-0134UP]
5. Fauci A.S, Kasper D.L, Longo D.L, Brauneald E, Hauser S.L, Jameson J.L, Loscalzo J. Choronic obstructive pulmonary disease. Available in: Harrison's Principles of Internal Medicine.17 ed, 2007; chapter 254.
6. Buist AS, McBurnie MA, Vollmer WM, Gillespie S, Burney P, Mannino DM, Menezes AM, Sullivan SD, Lee TA, Weiss KB, Jensen RL, Marks GB, Gulsvik A, Nizankowska-Mogilnicka E; BOLD Collaborative Research Group. International variation in the prevalence of COPD (the BOLD Study): a population-based prevalence study. Lancet 2007;370: 741-50. [17765523] [http://dx.doi.org/10.1016/S0140-6736(07)61377-4]
7. Dahl M, Vestbo J, Lange P, Bojesen SE, Tybjaerg-Hansen A, Nordestgaard BG. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-5. [17053205] [http://dx.doi.org/10.1164/rccm.200605-713OC]
8. Ridker PM. Clinical application of Creactive protein for cardiovascular disease detection and prevention. Circulation 2003;107:363-9. [12551 853] [http://dx.doi.org/10.1161/01. CIR.0000053730.47739.3C]
9. Morissette MC, Vachon-Beaudoin G, Parent J, Chakir J, Milot J. Increased p53 level, Bax/Bcl-x(L) ratio, and TRAIL receptor expression in human emphysema. Am J Respir Crit Care Med 2008;178:240-7. [185 11705] [http://dx.doi.org/10.1164/rccm.200710-1486OC]
10. Hodge S, Hodge G, Jersmann H, Matthews G, Ahern J, Holmes M, Reynolds PN. Azithromycin improves macrophage phagocytic function and expression of mannose receptor in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2008;178:139-48. [1842 0960] [http://dx.doi.org/10.1164/rccm.200711-1666OC]
11. Breyer MK, Spruit MA, Celis AP, Rutten EP, Janssen PP, Wouters EF; CIRO Network. Highly elevated C-reactive protein levels in obese patients with COPD: A fat chance? Clin Nutr 2009;28:642-7. [19540024] [http://dx.doi.org/10.1016/j.clnu.2009.05.005]
12. Attaran D, Lari SM, Khajehdaluee M, Ayatollahi H, Towhidi M, Asnaashari A, Marallu HG, Mazloomi M, Mood MB. Highly sensitive Creactive protein levels in Iranian patients with pulmonarycomplications of sulfur mustard poisoning &its correlation with severity of airway diseases. Hum Exp Toxicol 2009; 28:739-45. [19919970] [http://dx. doi.org/10.1177/0960327109354311]
13. de Torres JP, Pinto-Plata V, Casanova C, Mullerova H, Córdoba-Lanús E, Muros de Fuentes M, Aguirre-Jaime A, Celli BR. Creactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008;133: 1336-43. [18339787] [http://dx.doi. org/10.1378/chest.07-2433]
14. de Torres JP, Cordoba-Lanus E, López-Aguilar C, Muros de Fuentes M, Montejo de Garcini A, Aguirre-Jaime A, Celli BR, Casanova C. Creactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006;27:902-7. [16455829]
15. Halvani A, Nadooshan HH, Shoraki FK, Nasiriani K. Serum C-Reactive Protein Level in COPD Patients and Normal Population. Tanaffos 2007; 6:51-55.
16. Shaaban R, Kony S, Driss F, Leynaert B, Soussan D, Pin I, Neukirch F, Zureik M. Change in Creactive protein levels and FEV1 decline: A longitudinal populationbased study. Respir Med 2006; 100:2112-20. [16650972] [http://dx. doi.org/10.1016/j.rmed.2006.03.027]
17. Pinto-Plata VM, Müllerova H, Toso JF, Feudjo-Tepie M, Soriano JB, Vessey RS, Celli BR. C-reactive protein in patients with COPD, control smokers and non-smokers. Thorax 2006;61:23-8. [16143583] [http:// dx.doi.org/10.1136/thx.2005.042200]
18. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, Maccallum PK, Wedzicha JA. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128:1995-2004. [16236847] [http:// dx.doi.org/10.1378/chest.128.4.1995]
19. Bircan A, Gokirmak M, Kilic O, Ozturk O, Akkaya A. C-Reactive Protein Levels in Patients with Chronic Obstructive Pulmonary Disease: Role of Infection. Med Princ Pract 2008;17:202-8. [18408388] [http://dx.doi.org/10.1159/000117793]
20. Rezayitalab F, Dastani M, Rashed T, Salari M. Survey on the relationship of CRP and Pulmonary artery pressure in COPD patients. Mashhad University Journal 2009;52:95-100.